Eurican P

Land: Vereinigtes Königreich

Sprache: Englisch

Quelle: VMD (Veterinary Medicines Directorate)

Wirkstoff:

Canine parvovirus

Verfügbar ab:

Merial Animal Health Limited

ATC-Code:

QI07AD01

INN (Internationale Bezeichnung):

Canine parvovirus

Darreichungsform:

Suspension for injection

Verschreibungstyp:

POM-V - Prescription Only Medicine – Veterinarian

Therapiegruppe:

Dogs

Therapiebereich:

Live Viral Vaccine

Berechtigungsstatus:

Expired

Berechtigungsdatum:

2005-10-28

Fachinformation

Revised: May 2012
AN: 02062/2012
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
EURICAN P
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 ml dose of vaccine contains
Freeze-dried pellet:
Attenuated canine parvovirus
………………………………………..

10
4.9
CCID
50
Excipients qs 1 dose
CCID
50
= 50% cell culture infective dose.
For full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Lyophilisate for suspension
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs and puppies from 8 weeks of age.
4.2
INDICATIONS FOR USE SPECIFYING THE TARGET SPECIES
Active immunisation of dogs from 8 weeks of age to prevent clinical
signs and
to reduce mortality and viral excretion caused by canine parvovirosis
infection.
Onset of immunity : 7 days after primary vaccination.
Duration of immunity: 2 years.
4.3
CONTRA-INDICATIONS
None.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None
Revised: May 2012
AN: 02062/2012
Page 2 of 4
4.5
SPECIAL PRECAUTIONS FOR USE, INCLUDING SPECIAL PRECAUTIONS TO BE TAKEN
BY THE PERSON ADMINISTERING THE MEDICINAL PRODUCT TO ANIMALS
i. Special precautions for use in animals
The CPV vaccine strain of EURICAN P may be shed from
vaccinated animals for a number of days following vaccination.
However, due to the absence of pathogenicity of the strain, it is not
necessary to keep vaccinated animals separated from non–
vaccinated animals.
ii. Special precautions to be taken by the person administering the
medicinal product to animals
In case of accidental self-injection, seek medical advice
immediately and show this package insert or the label to the
physician.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
In rare cases, slight and transient pain may be apparent at the time
of injection,
which regresses within 2 hours.
In exceptional circumstances a hypersensitivity reaction may occur
which
may require appropriate symptomatic treatment.
4.7
USE DURING PREGNANCY, LACTATION OR LAY
Can be used during pregnancy. In the absence of data fro